{"id":"W4389233179","doi":"10.1182/blood-2023-174718","title":"Traverse: A Phase 2, Open-Label, Randomized Study of Acalabrutinib in Combination with Venetoclax and Rituximab in Patients with Treatment-Naive Mantle Cell Lymphoma","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Mantle cell lymphoma; Rituximab; Internal medicine; Oncology; Venetoclax; Ibrutinib; Chemoimmunotherapy; Lymphoma; Gastroenterology; Chronic lymphocytic leukemia; Leukemia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001621988,0.001519728,0.002020246,0.000498639,0.0004538355,0.001387572,0.0009944276,0.001575887,0.007014917],"category_scores_gemma":[0.00143663,0.0006660526,0.001360504,0.0004976824,0.00104496,0.001406676,0.000451099,0.003084771,0.001043687],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00110584,"about_ca_system_score_gemma":0.00143281,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000873279,"about_ca_topic_score_gemma":0.003063254,"domain_scores_codex":[0.9993116,0.0003889636,0.00002674667,0.000115385,0.00005684215,0.0001004379],"domain_scores_gemma":[0.9991993,0.0001414095,0.0002094404,0.00005251178,0.00004961338,0.0003476672],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9215893,0.0254443,0.002658179,0.0009307631,0.001687376,0.0001432591,0.0001640922,0.0005769509,0.009466399,0.0002991159,0.003541632,0.03349868],"study_design_scores_gemma":[0.8975487,0.0967463,0.002556423,0.00002801684,0.0003982739,0.0001164933,0.0000352955,0.0004056241,0.0002631035,0.0001291942,0.001754548,0.00001803543],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9817043,0.0056148,0.000659907,0.001049647,0.0003975724,0.004763896,0.001601062,0.0002573226,0.003951592],"genre_scores_gemma":[0.9809168,0.00284054,0.002100299,0.002276078,0.0004925714,0.005955833,0.002021186,0.00004317307,0.003353538],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007014917,"threshold_uncertainty_score":0.0234673,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02358003933382442,"score_gpt":0.3151918053041063,"score_spread":0.2916117659702819,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}